{"url_path":"/sec/bold/8-k/2026-06-23/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1782303/0001193125-26-278570-index.html","accession_number":"0001193125-26-278570","cik":"0001782303","ticker":"BOLD","issuer_name":"Boundless Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782303/0001193125-26-278570-index.html","primary_entity_key":"0001782303","primary_entity_name":"Boundless Bio, Inc."},"word_count":57,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nBased on preliminary exposure data obtained in the early dose escalation cohorts of the KOMODO-1 clinical trial, Boundless Bio believed that the observed pharmacokinetic exposure data, indicating that human oral bioavailability of BBI-940 was significantly lower than what had been predicted based on preclinical studies, did not support continued clinical development of BBI-940."}